Mirum Pharmaceuticals Projects 2026 Net Product Sales Between $715M and $720M
Mirum Pharmaceuticals reported strong third-quarter performance, driven by robust commercial activity and progress across its clinical programs. The company achieved $186 million in net product sales during the third quarter, reflecting significant market traction for its current portfolio. Looking ahead, management has provided optimistic long-term guidance, forecasting 2026 net product sales to reach between $715 million and $720 million. Additionally, the company is targeting a transition to positive cash flow by next year, signaling an improving financial profile as it scales its operations.
Tickers: $MIRM